These promising results-from an NIH-funded study that exclusively evaluated Masimo SET ® in a vulnerable, clinically fragile patient population-add to previously published evidence of its strong ...
Multinational Real-world Data Reinforce Favorable Clinical Profile and Long-Term Safety SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today ...
CytokineticsCYTK stock surged Tuesday on positive results in a heart disease study where its chief rival, Bristol Myers Squibb'sBMY Camzyos, previously failed. The study, dubbed Acacia-HCM, tested ...
Investing.com -- Cytokinetics (NASDAQ:CYTK) shares rose 28% Tuesday following positive topline results from ACACIA-HCM, the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic non ...
The KCCQ-CSS showed a difference of 3.0 points (p=0.021) between aficamten and placebo, while pVO2 showed a difference of 0.67 mL/kg/min (p=0.003). ACACIA-HCM randomized and treated 516 participants ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results